Although the abovementioned findings show that NHE1 might be a novel treatment target against brain tumorigenesis and progression, there are no clinical studies to date evaluating the pharmacological inhibition of NHE1 protein in brain tumors [68]. Here, SLC9A1 is linked to brain neoplasm.